Want to see BIO full AI Analyst Report?
BIO Stock Chart & Stats
$314.46
$1.95(0.62%)
At close: 4:00 PM EDT
$314.46
$1.95(0.62%)
Day’s Range― - ―
52-Week Range$236.73 - $385.92
Previous Close$316.41
Volume348.91K
Average Volume (3M)299.95K
Market Cap
$10.01B
Enterprise Value$7.62K
Total Cash (Recent Filing)$1.62B
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)45.6
Beta0.73
Next Earnings
Oct 22, 2026EPS Estimate
2.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.33
Shares Outstanding21,677,137
10 Day Avg. Volume308,348
30 Day Avg. Volume299,952
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.11
Price to Sales (P/S)3.20
P/FCF Ratio22.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$350.00Price Target Upside11.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)9.04
Revenue Forecast (FY)$2.58B
Bulls Say, Bears Say
Bulls Say
Product PerformanceProcess chromatography grew mid-teens percentage in the quarter, and management was constructive on consumables overall.
Bears Say
Financial PerformanceForecasts for Bio-Rad's revenue and adjusted EBITDA have been reduced, reflecting a less optimistic outlook.
Growth ForecastBio-Rad Laboratories is expected to experience lower growth in their Life Sciences segment due to recent US policy changes and uncertainty around NIH funding.
Bio-Rad Laboratories News
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
Bio-Rad Laboratories lowest stock price was $236.73 and its highest was $385.92 in the past 12 months.
What is Bio-Rad Laboratories’s market cap?
Bio-Rad Laboratories’s market cap is $10.01B.
When is Bio-Rad Laboratories’s upcoming earnings report date?
Bio-Rad Laboratories’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were Bio-Rad Laboratories’s earnings last quarter?
Bio-Rad Laboratories released its earnings results on Aug 04, 2026. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.748 by $0.872.
Is Bio-Rad Laboratories overvalued?
According to Wall Street analysts Bio-Rad Laboratories’s price is currently Undervalued.
Does Bio-Rad Laboratories pay dividends?
Bio-Rad Laboratories does not currently pay dividends.
What is Bio-Rad Laboratories’s EPS estimate?
Bio-Rad Laboratories’s EPS estimate is 2.23.
How many shares outstanding does Bio-Rad Laboratories have?
Bio-Rad Laboratories has 21,677,137 shares outstanding.
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Bio-Rad Laboratories reported an EPS of $2.62 in its last earnings report, beating expectations of $1.748. Following the earnings report the stock price went up 4.5%.
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
Currently, no hedge funds are holding shares in BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Rad Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$350.00 (11.30% Upside)
$350.00 (11.30% Upside)
Blogger Sentiment
Neutral
BIO Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 139.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
BIO Company Deck
BIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call showed a mix of encouraging operational and strategic progress alongside meaningful near-term headwinds. Positives include a strong sequential recovery (Q2 up ~10% vs Q1), clinical diagnostics returning to growth (+8.3% CC), ddPCR momentum (6% revenue growth, >20% instrument growth), improved sequential operating performance, and disciplined capital actions (Stilla acquisition accretive, $32M buyback, $30–35M annualized cost savings target). Offsetting these are persistent Life Science weakness (-5.1% CC), a steep decline in China (high-teens), consumables pull-through lag, process chromatography lumpiness, higher SG&A and logistics costs, and a cautious full-year revenue framework that allows for modest contraction. Overall, positives and negatives are roughly balanced: strategic momentum and margin recovery are clear, but near-term top-line and region-specific headwinds temper the outlook.View all BIO earnings summariesBIO Net sales Breakdown
39.53% Life Science
60.47% Clinical Diagnostics
0.00% Other Operations

BIO Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$350.00
▲(11.30% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
22.65% Insiders
34.20% Mutual Funds
22.16% Other Institutional Investors
3.77% Public Companies and
Individual Investors








